

Rhine®

Ranitidine

Description:

Rhine® (Ranitidine) is a histamine H₂-receptor antagonist. It is several times potent than cimetidine on the basis of molecular weight. It inhibits gastric acid secretion & the inhibition is competitive & reversible. It inhibits both day time & nocturnal basal gastric acid secretion as well as gastric acid secretion stimulated by food.

Rhine® is capsule shape film coated tablet containing Ranitidine Hydrochloride USP equivalent to Ranitidine 150 mg. **Rhine® Effervescent** tablet containing Ranitidine Hydrochloride USP equivalent to Ranitidine 150 mg. One tablet dissolve in a glass of water before consumption.

Indications:

- ▶ Treatment of active duodenal ulcer
- ▶ Benign gastric ulcer
- ▶ Treatment & prevention of ulcer associated with non-steroidal anti-inflammatory agent
- ▶ Post operative stress ulcer
- ▶ Zollinger-Ellison Syndrome
- ▶ Gastroesophageal reflux disease (GERD)
- ▶ Gastrointestinal hemorrhage from stress ulcer in seriously ill patient
- ▶ Recurrent hemorrhage in patients with bleeding peptic ulcer
- ▶ Before general anesthesia in patient considered to be at risk of acid aspiration particularly obstetric patients

Mode of Action:

Rhine® (Ranitidine) is a specific, rapidly acting histamine H₂ receptor-antagonist. It inhibits basal and stimulated secretion of gastric acid.

Rhine® (Ranitidine) has a relatively long duration of action & so a single 150 mg dose effectively suppresses gastric acid secretion for twelve hours.

Absorption, Fate & Excretion:

As a group H₂-antagonists are rapidly well absorbed after oral administration; peak concentrations in plasma are attained within 1 or 2 hours.

The half-life for elimination of Ranitidine is 2 to 3 hours. These drugs are in large part excreted in the urine without being metabolized. However, the half-life of Ranitidine is significantly prolonged in patients with hepatic dysfunction.

Dosage & Administration:

Adult: The usual dose of **Rhine®** (Ranitidine) is 150 mg twice daily (in the morning & at bed time). In the management of duodenal & gastric ulcer a single daily dose of 300 mg at bed time can be given as an alternative to twice daily administration & treatment should be given initially for at least 4 weeks. Where appropriate, maintenance dose of 150 mg daily may be given at bed time.

In reflux oesophagitis the recommended dose is 150 mg twice daily or 300 mg at bed time for up to 8 weeks. In pathological hypersecretory conditions, such as Zollinger-Ellison Syndrome initial dose is usually 150 mg twice or thrice daily & may be increased up to 6 gm daily.

Side Effects:

Rarely dizziness, insomnia, reversible mental confusion, depression, diarrhoea, nausea, vomiting, abdominal discomfort. Hallucination have been reported, predominately in severely ill elderly patients. Hepatitis anaphylactoid reaction, thrombocytopenia and leucopenia occur rarely.

Precautions:

Since **Rhine®** (Ranitidine) is excreted primarily by the Kidney, dosage should be adjusted in patients with impaired renal function. Caution should be taken in patients with hepatic dysfunction.

Drug Interactions:

Increased or decreased prothrombin times have been reported during concurrent use of **Rhine®** (Ranitidine) and Warfarin. However, in human pharmacokinetics studies with dosage of Ranitidine up to 400 mg per day, no interaction occurred, combined use of Ranitidine and Sucralfate should be avoided because the latter works best in acid medium. Absorption of Ketoconazole is decreased when used with **Rhine®** (Ranitidine).

Use in Pregnancy and Lactation:

Safety of **Rhine®** (Ranitidine) during pregnancy has not been established. This drug should be used during pregnancy only if clearly needed. Ranitidine is secreted in human milk, caution should be exercised when it is administered to nursing mother.

Contraindication:

Patients hypersensitive to **Rhine®** (Ranitidine).

Pharmaceutical Precautions:

Store in a cool and dry place below 30°C. Protect from light.

Supply:

Rhine® 150 mg Tablet: Each box contains 2x10's/3x10's/4x10's/5x10's/6x10's in Alu-Alu blister Pack.

Rhine® Effervescent 150 mg Tablet: Each box contains 2x10's/3x10's/4x10's/5x10's/6x10's in blister Pack.

Medicine: Keep out of reach of children



Made in Bangladesh by:

Healthcare Pharmaceuticals Limited
Rajendrapur